Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo

被引：32

作者：

Arreba-Tutusaus, P. ^{[1
]}

Mack, T. S. ^{[1
]}

Bullinger, L. ^{[2
,3
,4
]}

Schnoeder, T. M. ^{[1
]}

Polanetzki, A. ^{[1
]}

Weinert, S. ^{[5
]}

Ballaschk, A. ^{[1
]}

Wang, Z. ^{[3
,4
]}

Deshpande, A. J. ^{[3
,4
,6
]}

Armstrong, S. A. ^{[3
,4
,7
,8
]}

Doehner, K. ^{[2
]}

Fischer, T. ^{[1
]}

Heidel, F. H. ^{[1
]}

机构：

[1] Univ Magdeburg, Ctr Internal Med, Dept Hematol & Oncol, D-39106 Magdeburg, Saxony Anhalt, Germany

[2] Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Baden Wurttembe, Germany

[3] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA

[4] Harvard Univ, Sch Med, Boston, MA USA

[5] Univ Magdeburg, Ctr Internal Med, Dept Cardiol & Angiol, D-39106 Magdeburg, Saxony Anhalt, Germany

[6] Sanford Burnham Med Res Inst, Tumor Initiat & Maintenance, La Jolla, CA USA

[7] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY USA

[8] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY USA

来源：

LEUKEMIA | 2016年 / 30卷 / 05期

关键词：

ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; KINASE INHIBITOR; MUTATIONS; EXPRESSION; IMATINIB; PKC412; GENE; SIZE;

D O I：

10.1038/leu.2015.292

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1220 / 1225

页数：7

共 16 条

[1] Molecular analysis of different FLT3-ITD mutations in acute myeloid leukemia [J].

Blau, Olga ;

Berenstein, Rimma ;

Sindram, Annette ;

Blau, Igor Wolfgang .

LEUKEMIA & LYMPHOMA, 2013, 54 (01) :145-152

[2] Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor [J].

Breitenbuecher, Frank ;

Schnittger, Susanne ;

Grundler, Rebekka ;

Markova, Boyka ;

Carius, Birgit ;

Brecht, Alexandra ;

Duyster, Justus ;

Haferlach, Torsten ;

Huber, Christoph ;

Fischer, Thomas .

BLOOD, 2009, 113 (17) :4074-4077

[3] An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML [J].

Bullinger, Lars ;

Doehner, Konstanze ;

Kranz, Raphael ;

Stirner, Christoph ;

Froeling, Stefan ;

Scholl, Claudia ;

Kim, Young H. ;

Schlenk, Richard F. ;

Tibshirani, Robert ;

Doehner, Hartmut ;

Pollack, Jonathan R. .

BLOOD, 2008, 111 (09) :4490-4495

[4] Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients [J].

Carmen Chillon, Maria ;

Santamaria, Carlos ;

Garcia-Sanz, Ramon ;

Balanzategui, Ana ;

Eugenia Sarasquete, Maria ;

Alcoceba, Miguel ;

Marin, Luis ;

Dolores Caballero, Maria ;

Belen Vidriales, Maria ;

Ramos, Fernando ;

Bernal, Teresa ;

Diaz-Mediavilla, Joaquin ;

Garcia de Coca, Alfonso ;

Jesus Penarrubia, Maria ;

Antonio Queizan, Jose ;

Giraldo, Pilar ;

San Miguel, Jesus F. ;

Gonzalez, Marcos .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (05) :745-751

[5] Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3 [J].

Fischer, Thomas ;

Stone, Richard M. ;

DeAngelo, Daniel J. ;

Galinsky, Ilene ;

Estey, Elihu ;

Lanza, Carlo ;

Fox, Edward ;

Ehninger, Gerhard ;

Feldman, Eric J. ;

Schiller, Gary J. ;

Klimek, Virginia M. ;

Nimer, Stephen D. ;

Gilliland, D. Gary ;

Dutreix, Catherine ;

Huntsman-Labed, Alice ;

Virkus, Jodi ;

Giles, Francis J. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) :4339-4345

[6] The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia [J].

Gale, Rosemary E. ;

Green, Claire ;

Allen, Christopher ;

Mead, Adam J. ;

Burnett, Alan K. ;

Hils, Robert K. ;

Linch, David C. .

BLOOD, 2008, 111 (05) :2776-2784

[7] Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain [J].

Heidel, F ;

Solem, FK ;

Breitenbuecher, F ;

Lipka, DB ;

Kasper, S ;

Thiede, MH ;

Brandts, C ;

Serve, H ;

Roesel, J ;

Giles, F ;

Feldman, E ;

Ehninger, G ;

Schiller, GJ ;

Nimer, S ;

Stone, RM ;

Wang, YF ;

Kindler, T ;

Cohen, PS ;

Huber, C ;

Fischer, T .

BLOOD, 2006, 107 (01) :293-300

[8] Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML [J].

Heidel, Florian H. ;

Bullinger, Lars ;

Feng, Zhaohui ;

Wang, Zhu ;

Neff, Tobias A. ;

Stein, Lauren ;

Kalaitzidis, Demetrios ;

Lane, Steve W. ;

Armstrong, Scott A. .

CELL STEM CELL, 2012, 10 (04) :412-424

[9] Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome [J].

Kayser, Sabine ;

Schlenk, Richard F. ;

Londono, Martina Correa ;

Breitenbuecher, Frank ;

Wittke, Kerstin ;

Du, Juan ;

Groner, Silja ;

Spaeth, Daniela ;

Krauter, Juergen ;

Ganser, Arnold ;

Doehner, Hartmut ;

Fischer, Thomas ;

Doehner, Konstanze .

BLOOD, 2009, 114 (12) :2386-2392

[10] FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model [J].

Kelly, LM ;

Liu, Q ;

Kutok, JL ;

Williams, IR ;

Boulton, CL ;

Gilliland, DG .

BLOOD, 2002, 99 (01) :310-318

← 1 2 →